Figure 30. KQ4 Withdrawal due to adverse events base case analysis —Meta-analysis of randomized placebo-controlled trials comparing ACEI or ARB with CCB in patients with stable is chemic heart disease.

Figure 30KQ4 Withdrawal due to adverse events base case analysis —Meta-analysis of randomized placebo-controlled trials comparing ACEI or ARB with CCB in patients with stable is chemic heart disease

Test for heterogeneity: Cochran Q=3.367103 (df=1) p=0.0.0665; I2 statistic=87.2%

Note: The square represent individual point estimates. The size of the square represents the weight given to each study in the meta-analysis. Horizontal lines through each square represent 95% confidence intervals. The diamond represents the combined results. The solid vertical line extending from 1 is the null value.

From: Results

Cover of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [Internet].
Comparative Effectiveness Reviews, No. 18.
Coleman CI, Baker WL, Kluger J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.